86 related articles for article (PubMed ID: 9029997)
1. Excessive sweating: unusual side effect of megestrol acetate therapy.
Votaw ML
Tenn Med; 1997 Feb; 90(2):59. PubMed ID: 9029997
[No Abstract] [Full Text] [Related]
2. Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
Bland KI; Buzdar AU
Ann Surg Oncol; 1999 Dec; 6(8 Suppl):12S-13S. PubMed ID: 10619454
[No Abstract] [Full Text] [Related]
3. Clinical adrenal insufficiency in patients receiving megestrol therapy.
Subramanian S; Goker H; Kanji A; Sweeney H
Arch Intern Med; 1997 May; 157(9):1008-11. PubMed ID: 9140272
[TBL] [Abstract][Full Text] [Related]
4. Megestrol acetate-induced adrenal insufficiency.
González Villarroel P; Fernández Pérez I; Páramo C; Gentil González M; Carnero López B; Vázquez Tuñas ML; Carrasco Alvarez JA
Clin Transl Oncol; 2008 Apr; 10(4):235-7. PubMed ID: 18411198
[TBL] [Abstract][Full Text] [Related]
5. [Megestrol acetate as hormone therapy in oncology].
Berstein LM
Vopr Onkol; 1998; 44(2):142-8. PubMed ID: 9615815
[TBL] [Abstract][Full Text] [Related]
6. Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy.
Gruber TJ; Fabiano AJ; Deeb G; Lele SB; Fenstermaker RA
World Neurosurg; 2011 Nov; 76(5):477.e16-20. PubMed ID: 22152580
[TBL] [Abstract][Full Text] [Related]
7. Megestrol acetate therapy and secondary adrenal suppression.
Naing KK; Dewar JA; Leese GP
Cancer; 1999 Sep; 86(6):1044-9. PubMed ID: 10491532
[TBL] [Abstract][Full Text] [Related]
8. Megestrol acetate-caused adrenal insufficiency and delayed puberty in a male adolescent with spinal tumour.
Leelalertlauw C; Mahachoklertwattana P; Hongeng S; Poomthavorn P
J Paediatr Child Health; 2018 Feb; 54(2):194-196. PubMed ID: 29024203
[No Abstract] [Full Text] [Related]
9. Hormonal effect on meningioma growth.
Shahar T; Ram Z
World Neurosurg; 2011 Nov; 76(5):412-4. PubMed ID: 22152568
[No Abstract] [Full Text] [Related]
10. [Current views on use of megestrol acetate in oncology practice].
Vyzula R
Vnitr Lek; 1997 Apr; 43(4):250-5. PubMed ID: 9601846
[TBL] [Abstract][Full Text] [Related]
11. Primary symptomatic adrenal insufficiency induced by megestrol acetate.
Delitala AP; Fanciulli G; Maioli M; Piga G; Delitala G
Neth J Med; 2013 Jan; 71(1):17-21. PubMed ID: 23412818
[TBL] [Abstract][Full Text] [Related]
12. Future directions in endocrine treatment of advanced breast cancer.
Bland KI
Ann Surg Oncol; 1999 Dec; 6(8 Suppl):14S-16S. PubMed ID: 10619455
[No Abstract] [Full Text] [Related]
13. [Hormonal therapy and chemotherapy of endometrial cancer].
Krauss T; Huschmand H; Hinney B; Viereck V; Emons G
Zentralbl Gynakol; 2002 Jan; 124(1):45-50. PubMed ID: 11873314
[TBL] [Abstract][Full Text] [Related]
14. Meningioma-toward an improved understanding of the role of sex steroids in tumor development and progression.
Elder JB; Chiocca EA
World Neurosurg; 2011 Nov; 76(5):409-11. PubMed ID: 22152567
[No Abstract] [Full Text] [Related]
15. Hemostatic effects of high-dose megestrol acetate therapy in patients with advanced gynecological cancer.
Oberhoff C; Hoffmann O; Winkler UH; Schindler AE
Gynecol Endocrinol; 2001 Oct; 15(5):341-8. PubMed ID: 11727356
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients--longterm follow-up.
Fjøsne HE; Jacobsen AB; Lundgren S;
Eur J Surg Oncol; 2008 Jan; 34(1):6-12. PubMed ID: 17881183
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Buzdar AU; Jonat W; Howell A; Jones SE; Blomqvist CP; Vogel CL; Eiermann W; Wolter JM; Steinberg M; Webster A; Lee D
Cancer; 1998 Sep; 83(6):1142-52. PubMed ID: 9740079
[TBL] [Abstract][Full Text] [Related]
18. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.
Dawson NA; Conaway M; Halabi S; Winer EP; Small EJ; Lake D; Vogelzang NJ
Cancer; 2000 Feb; 88(4):825-34. PubMed ID: 10679652
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C).
Andersen J; Kamby C; Ejlertsen B; Cold S; Ewertz M; Jacobsen EH; Philip P; Møller KA; Jensen D; Møller S
Acta Oncol; 2008; 47(4):718-24. PubMed ID: 18465340
[TBL] [Abstract][Full Text] [Related]
20. Medroxyprogesterone acetate induced Cushing's syndrome.
Shotliff K; Nussey SS
Br J Clin Pharmacol; 1997 Sep; 44(3):304. PubMed ID: 9296330
[No Abstract] [Full Text] [Related]
[Next] [New Search]
